Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria

• DOI: 10.1007/s13300-022-01218-y
• Publication Date: 2022-03-01T10:02:56Z
• Authors: Chiara Di Loreto; Viviana Minarelli; Giovanni Nasini; Roberto Norgiolini; Paola Del Sindaco
• Keywords: Semaglutide; Discontinuation; Tolerability; Dulaglutide

To complement results of the SUSTAIN program, this study assessed effectiveness and safety once weekly subcutaneous semaglutide in people with type 2 diabetes (T2D) managed under routine care.This was a multicenter, observational, retrospective including all patients treated semaglutide. Changes clinical outcomes from baseline to 6 12 months were who glucagon-like peptide receptor agonist (GLP-1RA) naïve or switching another GLP-1RA. Discontinuation rate assessed.Overall, 216 (mean age 64 years, 65.7% men) evaluated: 135 (61.5%) 81 (38.5%) switchers In cohort, after initiation, levels HbA1c significantly decreased by - 1.31% (p < 0.0001). All obesity indices improved, mean reductions body weight 3.92 kg, BMI 1.43 kg/m2, waist circumference 5.03 cm. switcher statistically significant improvements (- 0.78%), 2.64 kg), 3.03 cm) obtained months. Reductions sustained both cohorts dose: 0.86 mg 0.96 cohort). Blood pressure lipid profile initiation cohorts. No severe hypoglycemia occurred; 6.5% discontinued (2.8% due gastrointestinal side effects).Effectiveness tolerability have been confirmed real world irrespective duration severity. As expected, more marked patients, but it is noteworthy that relevant also already GLP-1RAs.